DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease

In brief

This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces antibodies against Alzheimer's disease-related proteins.

Key facts

Study ID
NCT07142278
Run by
Nuravax, Inc.
People needed
24
Starts
2025-11-01
Expected to finish
2027-07-31
Last updated by the study team
2025-10-22

Who can join

Age: 40 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.